Literature DB >> 32959120

Breast cancer screening for women at high risk: review of current guidelines from leading specialty societies.

Natsuko Onishi1, Masako Kataoka2.   

Abstract

The purpose of this article is to overview the existing breast cancer screening guidelines for women at high risk from world-leading specialty societies. Accumulation of evidence and development of accessible genetic testing strategies have changed the idea of breast cancer screening for high-risk women. Personalized tailor-made screening adjusted for risk factors has been conducted in accordance with guidelines. The use of imaging modalities other than mammography including contrast-enhanced MRI and other various strategies for improving screening are discussed. The present review also mentions the existing challenges in high-risk screening and the latest information based on two large-scale studies.
© 2020. The Japanese Breast Cancer Society.

Entities:  

Keywords:  Breast cancer screening; High risk; Magnetic resonance imaging; Mammography; Risk-stratified screening

Mesh:

Substances:

Year:  2020        PMID: 32959120     DOI: 10.1007/s12282-020-01157-1

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  99 in total

1.  A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.

Authors:  D G R Evans; D M Eccles; N Rahman; K Young; M Bulman; E Amir; A Shenton; A Howell; F Lalloo
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

2.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

Authors:  A Antoniou; P D P Pharoah; S Narod; H A Risch; J E Eyfjord; J L Hopper; N Loman; H Olsson; O Johannsson; A Borg; B Pasini; P Radice; S Manoukian; D M Eccles; N Tang; E Olah; H Anton-Culver; E Warner; J Lubinski; J Gronwald; B Gorski; H Tulinius; S Thorlacius; H Eerola; H Nevanlinna; K Syrjäkoski; O-P Kallioniemi; D Thompson; C Evans; J Peto; F Lalloo; D G Evans; D F Easton
Journal:  Am J Hum Genet       Date:  2003-04-03       Impact factor: 11.025

3.  Effect of screening and adjuvant therapy on mortality from breast cancer.

Authors:  Donald A Berry; Kathleen A Cronin; Sylvia K Plevritis; Dennis G Fryback; Lauren Clarke; Marvin Zelen; Jeanne S Mandelblatt; Andrei Y Yakovlev; J Dik F Habbema; Eric J Feuer
Journal:  N Engl J Med       Date:  2005-10-27       Impact factor: 91.245

Review 4.  Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies.

Authors:  Sisse Njor; Lennarth Nyström; Sue Moss; Eugenio Paci; Mireille Broeders; Nereo Segnan; Elsebeth Lynge
Journal:  J Med Screen       Date:  2012       Impact factor: 2.136

5.  Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening.

Authors:  Kent F Hoskins; Alice Zwaagstra; Michael Ranz
Journal:  Cancer       Date:  2006-10-15       Impact factor: 6.860

6.  A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center.

Authors:  C A Gilpin; N Carson; A G Hunter
Journal:  Clin Genet       Date:  2000-10       Impact factor: 4.438

7.  Development and validation of a simple questionnaire for the identification of hereditary breast cancer in primary care.

Authors:  Patricia Ashton-Prolla; Juliana Giacomazzi; Aishameriane V Schmidt; Fernanda L Roth; Edenir I Palmero; Luciane Kalakun; Ernestina S Aguiar; Susana M Moreira; Erica Batassini; Vanessa Belo-Reyes; Lavinia Schuler-Faccini; Roberto Giugliani; Maira Caleffi; Suzi Alves Camey
Journal:  BMC Cancer       Date:  2009-08-14       Impact factor: 4.430

8.  Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population.

Authors:  Cecelia A Bellcross; Amy A Lemke; Laura S Pape; Angela L Tess; Lorraine T Meisner
Journal:  Genet Med       Date:  2009-11       Impact factor: 8.822

9.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

Authors:  Karoline B Kuchenbaecker; John L Hopper; Daniel R Barnes; Kelly-Anne Phillips; Thea M Mooij; Marie-José Roos-Blom; Sarah Jervis; Flora E van Leeuwen; Roger L Milne; Nadine Andrieu; David E Goldgar; Mary Beth Terry; Matti A Rookus; Douglas F Easton; Antonis C Antoniou; Lesley McGuffog; D Gareth Evans; Daniel Barrowdale; Debra Frost; Julian Adlard; Kai-Ren Ong; Louise Izatt; Marc Tischkowitz; Ros Eeles; Rosemarie Davidson; Shirley Hodgson; Steve Ellis; Catherine Nogues; Christine Lasset; Dominique Stoppa-Lyonnet; Jean-Pierre Fricker; Laurence Faivre; Pascaline Berthet; Maartje J Hooning; Lizet E van der Kolk; Carolien M Kets; Muriel A Adank; Esther M John; Wendy K Chung; Irene L Andrulis; Melissa Southey; Mary B Daly; Saundra S Buys; Ana Osorio; Christoph Engel; Karin Kast; Rita K Schmutzler; Trinidad Caldes; Anna Jakubowska; Jacques Simard; Michael L Friedlander; Sue-Anne McLachlan; Eva Machackova; Lenka Foretova; Yen Y Tan; Christian F Singer; Edith Olah; Anne-Marie Gerdes; Brita Arver; Håkan Olsson
Journal:  JAMA       Date:  2017-06-20       Impact factor: 56.272

10.  BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.

Authors:  A J Lee; A P Cunningham; K B Kuchenbaecker; N Mavaddat; D F Easton; A C Antoniou
Journal:  Br J Cancer       Date:  2013-12-17       Impact factor: 7.640

View more
  2 in total

Review 1.  Ultrafast Dynamic Contrast-enhanced MRI of the Breast: How Is It Used?

Authors:  Masako Kataoka; Maya Honda; Akane Ohashi; Ken Yamaguchi; Naoko Mori; Mariko Goto; Tomoyuki Fujioka; Mio Mori; Yutaka Kato; Hiroko Satake; Mami Iima; Kazunori Kubota
Journal:  Magn Reson Med Sci       Date:  2022-02-25       Impact factor: 2.760

2.  Editorial: HBOC and high-risk screening: up-to-date.

Authors:  Masako Kataoka
Journal:  Breast Cancer       Date:  2021-08-23       Impact factor: 4.239

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.